Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India

Abstract

ObjectiveTo ascertain the risk of spontaneous fetal loss (SPFL) in women with epilepsy (WWE) on antiepileptic drugs (AED), and explore the association between specific AED usage and risk of SPFL. MethodsWe identified all SPFL (including stillbirths) among pregnancies registered at Kerala Registry for Epilepsy and Pregnancy between 1998 and 2015. Rates of SPFL were compared between the AED exposed and unexposed groups. ResultsThere were 139 SPFL out of 1987 eligible pregnancies. The AED exposed had excess SPFL (7.4%, 134 out of 1809, Odds Ratio [OR] 2.77, 95% Confidence Interval [CI] 1.17–6.39) than AED unexposed (2.8%, 5 out of 178). The adjusted OR (95% CI) for SPFL for monotherapies with levetiracetam, phenobarbitone and clobazam were comparable to unexposed, while it was significantly higher for topiramate (OR 38.86, CI 5.02–301.19), lamotrigine (OR 13.33, CI 1.41–125.78), oxcarbazepine (OR 7.53, CI 1.54–36.89), valproate (OR 6.92, CI 1.70–28.18), phenytoin (OR 5.82, CI 1.43–23.73) and carbamazepine (OR 3.53, CI 1.15–10.90). With reference to levetiracetam, only topiramate had significantly higher SPFL (OR 11.14, CI 1.56–79.55). ConclusionSPFL risk is increased in pregnancies with AED exposure, being least with levetiracetam and highest with topiramate.